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Abstract
Background: Mitochondrial DNA (mtDNA) was reported as a pro-inflammatory agent. In our previous study,
elevation of plasma mtDNA was revealed after cardiac surgery with cardiopulmonary bypass (CPB). Platelets were
activated during the cardiac surgery and recent study revealed its ability to release mtDNA. Our present study
postulated that the elevated plasma mtDNA comes from activated platelets, which plays a critical role in post-CPB
inflammatory responses.
Methods: Sixty-eight patients who underwent coronary artery bypass graft (CABG) with CPB were enrolled in our
study. Blood samples were collected before induction of anaesthesia (T1), at the end of CPB (T2), 12 h post-CPB (T3),
24 h post-CPB (T4), 48 h post-CPB (T5) and 72 h post-CPB (T6). Blood samples were analyzed for the routine blood test
and prepared for plasma isolation. MtDNA concentration was measured by rt-PCR, and TNF-α and IL-6 were examined
by specific ELISA kits. Subgroup study was analyzed by activation levels of platelet. Basic information, mtDNA level,
TNF-α level and IL-6 level were all carefully studied in each quartile.
Results: Activation level of platelets increased and peaked at T2, which decreased gradually from T3 to T6 (P < 0.05).
MtDNA increased after CPB, peaked at T3, and then backed from T4 to T6 (P < 0.05). Bivariate correlation between peak
activation level of platelets and peak plasma mtDNA level showed a positive correlation between these two
parameters (r = 0.683, P < 0.0001). Both TNF-α and IL-6 showed similar patterns as mtDNA, with an increase from T1 to
T3 and a decrease from T4 to T6 (P < 0.05). Subgroup analysis further demonstrated that patients with higher activation
levels of PLT had higher plasma mtDNA levels and inflammatory level (P < 0.05).
Conclusions: Our study revealed the dynamic changes of activation level of platelets and identified the interesting
association between platelets activation and plasma mtDNA, suggesting a novel potential mechanism of activated
platelets-induced post-CPB inflammatory responses.
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Background
Cardiac surgery under cardiopulmonary bypass (CPB)
was firstly practiced in 1955 and reported by Kirklin JW,
providing a new horizon for modern cardio-thoracic sur-
geries [1]. CPB can help bypass the circulation out of
the heart and the lung, which offers a clear vision and
stable condition for operation [2]. Although the low
mortality for CPB is already analyzed, many harmful
events were still reported. Myocardial ischemic/reperfu-
sion injury (IRI) and abnormal status of circulation are
two major causes for post-operative systemic inflamma-
tory responses that take responsibilities for detrimental
effects on the heart and distant organs [3–5]. Much en-
deavor has already been taken to decrease these negative
effects. However, there is still lack of a sufficient way to
control post-operative systemic inflammatory responses.
Mitochondria are considered to be organelles evolved
both in saprophytic bacteria and endosymbiosis [6].
Mitochondrial DNA (mtDNA) consists of 16569
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nucleotide bases which code 13 polypeptides [7]. Con-
taining of CpG DNA repeats, mtDNA is widely studied
as a pro-inflammatory agent. Many experiments report el-
evated plasma mtDNA after injuries, which is released
into the circulation causing systemic inflammation [8, 9].
It is demonstrated that plasma mtDNA level can be used
to improve risk prediction and predict mortality [10].
Activation of platelets is revealed during the cardiac
surgery with CPB [11]. Dysfunction of platelets and se-
verely decreased platelets are also reported after CPB
[12]. Many studies are reported to use mean platelet vol-
ume/platelet count (MPV/platelet count) to represent
the activation level of platelets [13]. It is demonstrated
that activated platelets could release many pro-
inflammatory cytokines causing systemic inflammatory
responses [14]. Recently, Luc H. Boudreau, et al in-
formed that activated platelets could release mtDNA
into the circulation and promote inflammation through
serving as substrates for bactericidal group IIA [15].
Our previous study has revealed the variation of
plasma mtDNA level during and after cardiac surgery
with CPB. In the present study, given the mtDNA releas-
ing property of activated platelets, we postulated that
activated platelets might, at least partially, take the re-
sponsibility for the elevated plasma mtDNA during the
cardiac surgery with CPB. The present study aimed to
explore whether platelets activation was associated with
changes in levels of plasma mtDNA during CPB. Mean-
while, we also examined the relationship between plate-
let activation and inflammatory cytokines during CPB.
Method
Study population
Sixty-eight patients requiring coronary artery bypass
graft (CABG) with CPB were included consecutively
in our study from January 2014 to January 2015, who
were admitted to the Department of Cardiovascular
Surgery, West China Hospital, Sichuan University.
Medical history including endocarditis, diabetes,
hypertension, any infectious diseases, chronic inflam-
matory diseases, hematologic disorders that affect
platelet count or platelets function, autoimmune dis-
eases, post-operative acute renal failure, low cardiac
output syndrome were designed as the excluding cri-
teria. Pre-operative laboratory tests and examinations
were carefully arranged and all patients had normal
functions of kidney, liver and lung. Informed consents
were signed by every patient or their family members.
Post-operative standard care in cardiac intensive unit
(CICU) were scheduled as the routine element for all
patients. This protocol was conducted following the
Declaration of Helsinki and approved by the West
China Hospital Ethics Committee (No. 2012 (150)).
Collection of blood samples
Blood samples were collected in two EDTA-coated blood
collection tubes before induction of anaesthesia (T1), at
the end of CPB (T2), 12 h post-CPB (T3), 24 h post-
CPB (T4), 48 h post-CPB (T5) and 72 h post-CPB (T6).
One blood collection tube was for the routine blood test
immediately and results were reported by the Division of
Clinical Hematology, West China Hospital, Sichuan
University. The other tube was also immediately centri-
fuged at 1000 rpm/min for 15 min at 4 °C and the
supernatant was transferred to a new tube as plasma
without touching the pellet or the bottom of the tube.
All plasma samples were rapidly stored in −80 °C
freezer (Thermo, USA) and ready for the DNA isolation
and ELISA assay. All procedures were conducted care-
fully to avoid contamination.
DNA isolation and rt-PCR assay
The whole plasma DNA was isolated from plasma using
the DNeasy Blood and Tissue Kit (#69504, Qiagen) as
our previous report [16]. Briefly, 50 μL plasma sample
was added to 50 μL phosphate buffered saline (PBS) and
then centrifuged at 16000 g for 15 min at 4 °C. 90 μL of
supernatant were kept for the next procedures. The rest
procedures were performed exactly according to the
manufacture’s protocol. At the last step, 200 μL elution
buffer was added to resolve the DNA.
Plasma mtDNA levels were measured by SYBR-green
dye-based rt-PCR assay using a PRISM 7300 sequence
detection system. The primer sequences detecting
mtDNA were human NADH dehydrogenase 1 gene: for-
ward CGAGCAGTAGCCCAAACAAT, reverse TGTGA
TAAGGGTGGAGAGGTT. Plasmid DNA with comple-
mentary DNA sequence for human mtDNA was ob-
tained from ORIGENE (SC101172, USA). Concentration
of plasma mtDNA were converted to copy number via a
DNA copy number calculator (http://cels.uri.edu/gsc/
cndna.html; University of Rhode Island Genomics and
Sequencing Center). Plasmid DNA was diluted in 10-fold
serial dilutions and used as the standard curve. Every sam-
ples were studied three times for quality control.
All samples were measured with standards at the same
time. Plasma mtDNA levels were shown in copies per
microliter of plasma (copies/μL) according to the follow-
ing formula:
c ¼ Q  VDNA=VPCR  1=Vext
where c is the concentration of plasma mtDNA (cop-
ies/μL); Q means quantity of DNA measured by rt-PCR;
VDNA means the total volume of plasma DNA solution
obtained from extraction, 200 μL in this study; VPCR
means the volume of plasma DNA solution for rt-PCR,
Qin et al. Journal of Cardiothoracic Surgery  (2016) 11:90 Page 2 of 9
1 μL in this study; Vext means the volume of plasma
used for extraction, 50 μL in this study.
Plasma TNF-α and IL-6 measurement
Plasma TNF-α and IL-6 was measured by the enzyme-
linked immunosorbent assay (ELISA) kits, specifically
designed for human TNF-α and IL-6, respectively
(Solarbio, China). All procedures were carried out fol-
lowing the standard protocols (included in ELISA kits).
Three duplicated samples were set and all samples were
measured with serial diluted standards at the same
time. Spectrophotometry (VARIOSKAN, Thermo, USA)
was used to detect the intensity of the transmitted light.
Data was expressed in picogram per mL (pg/mL).
Statistical analysis
All descriptive data was shown as mean ± standard error
of the mean (SEM) and analyzed with SPSS statistical
software version 20.0 for Windows (SPSS, Inc. Chicago,
IL, USA). All descriptive data was near-normal by SPSS
analysis. Multiple comparisons were analyzed by the
one-way ANOVA followed by Bonferroni’s test. The
Pearson correlation coefficient test was performed to
analyze the relationship between MPV/platelet count
and plasma mtDNA. Data (platelet count, mtDNA, TNF-
α, IL-6) collected after T1 was corrected by hematocrit
(Hct) at T1 due to the hemodilution during cardiac sur-
gery (Datacorrected = Datacollection × HctT1/HctTx). P < 0.05
was considered as statistically significant.
Result
Baseline information
Basic characteristics, surgical information and laboratory
results of all patients were presented in Table 1. All
sixty-eight patients were successfully performed CABG
with CPB. No patient died or needed a second surgery
during the hospitalization. The average age and BMI
were (47.5 ± 15.2) years old and (24.1 ± 3.5). During sur-
gery, the average time of aortic cross-clamping and
total CPB were (64.3 ± 21.7) min and (96 ± 29.1) min,
respectively. On the first day admission, basic labora-
tory data such as serum creatinine, total cholesterol
(TC), high density lipoprotein (HDL), low density lipo-
protein (LDL), triglycerides (TG), glucose, red blood
cell count (RBC), white blood cell count (WBC), plate-
let count, MPV, hemoglobin (Hb) and Hct was col-
lected and represented.
Dynamic monitoring the activation of platelets
MPV/platelet count ratio was used to represent the activa-
tion level of platelets during the cardiac surgery. Through
serial six blood samples for each patient, dynamic changes
of activation level of platelets were monitored during the
cardiac surgery with CPB. As shown in Fig. 1, platelet
count, MPV and MPV/platelet count ratio were presented.
Compared with T1, platelet count significantly decreased
and touched the bottom at T2 (P < 0.05) following a grad-
ually increasing back to the baseline level from T3 to T6.
On the contrary, MPV increased significantly and reached
the highest level at T2 comparing with T1 (P < 0.05),
which dropped back to normal gradually. Therefore,
MPV/platelet count climbed to the peak at T2 and de-
creased gradually (P < 0.05). Our data demonstrated that
platelets were activated during the cardiac surgery with
CPB and the highest activation level of platelets occurred
at the end of CPB.
Plasma mtDNA changes and its correlation with peak
MPV/platelet count
Plasma samples were used to examine plasma mtDNA
levels by using rt-PCR technique (Data was shown in
Fig. 2a). As presented, changes of plasma mtDNA was
similar to MPV/platelet count, which increased
Table 1 Baseline information
Characteristics N = 68
Age (years) 47.5 ± 15.2
Women 41
BMI 24.1 ± 3.5






Aortic cross-clamping time (min) 64.3 ± 21.7
Total CPB time (min) 96.0 ± 29.1
Laboratory data
serum creatinine (μmol/L) 0.6 ± 0.3
Total cholesterol (mg/dL) 200.7 ± 41.3
HDL (mmol/L) 1.1 ± 0.3
LDL (mmol/L) 3.0 ± 0.5
TG (mmol/L) 1.7 ± 0.3
Glucose (mg/dL) 138.1 ± 31.4
RBC (×1012/L) 4.3 ± 0.4
WBC (×1012/L) 5.8 ± 1.3
platelet count (×109/L) 203 ± 49
MPV (fL) 10.2 ± 1.1
Hemoglobin (g/dL) 12.7 ± 1.4
Hematocrit (%) 38.3 ± 4.7
Variables are presented as mean ± SD or as numbers. BMI body mass index,
BSA body surface area, STEMI ST-segment myocardial infarction, NSTEMI Non-
ST-segment myocardial infarction, CPB cardiopulmonary bypass, HDL high
density lipoprotein, LDL low density lipoprotein, TG triglycerides, RBC red blood
cell, WBC white blood cell, MPV mean platelet volume
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significantly after T1 and decreased gradually from T4
to T6 (P < 0.05). However, the highest point happened at
T3 for plasma mtDNA.
To illustrate the relationship between platelets activa-
tion and plasma mtDNA, bivariate correlation analysis
was used. Since we excluded other possible complica-
tions that might disturb our results, the peak MPV/
platelet count and peak plasma mtDNA were used to
stand for platelets activation level and mtDNA releasing
level, respectively, during the cardiac surgery with CPB.
As shown in Fig. 2b, positive correlation was analyzed
between these two parameters (r = 0.683, P < 0.001).
These data demonstrated a close relationship between
platelets activation and plasma mtDNA.
Levels of TNF-α and IL-6
Plasma TNF-α and IL-6 levels were measured by ELISA
kits in all plasma samples. Data was presented in Fig. 3.
Both TNF-α and IL-6 increased since T2 and got the
highest level at T3, followed by a gradual decreasing
from T4 to T6 (P < 0.05). Consistence with previous
studies, our study confirmed dynamic changes of peri-
operative plasma TNF-α and IL-6 levels.
Subgroup analysis
According to our study, activation level of platelets
peaked at the end of CPB (T2) and the mean value of
MPV/platelet count was 0.12 ± 0.019 (0.069–0.162).
Distribution of study population was shown in Fig. 4.
Subgroups were defined as follow: Quartile 1, MPV/
platelet count <0.09 (N = 14); Quartile 2, MPV/platelet
count = 0.09–0.11 (N = 17); Quartile 3, MPV/platelet
count = 0.11–0.13 (N = 22); Quartile 4, MPV/platelet
count >0.13 (N = 15).
We analyzed the baseline information for each quar-
tile, shown in Table 2. Average age, BMI, time of aortic
cross-clamping, total CPB, serum creatinine, TC, HDL,
LDL, TG, glucose, RBC, WBC, Hb and Hct were care-
fully calculated and showed no significance between four
quartiles. Meanwhile, plasma mtDNA level, TNF-α and
IL-6 at 12 h post-CPB (T3) were also included to com-
pare among four quartiles. Intriguingly, significant dif-
ferences were observed among four quartiles. In
general, patients in the higher MPV/platelet count
quartiles had higher level of plasma mtDNA, TNF-α
and IL-6 (P < 0.05). The present study indicated that
higher levels of plasma mtDNA, TNF-α and IL-6 were
related to the higher MPV/platelet count quartiles, fur-
ther implying that mtDNA might come from activated
PLT and play a pro-inflammatory role.
Discussion
In our present study, we first dynamically monitored the
activation level of platelets by analyzing MPV/platelet
count ratio during the cardiac surgery with CPB, show-
ing that platelets activation level peaked at the end of
CPB. In addition, like our previous study, we revealed
the variation of plasma mtDNA and inflammatory cyto-
kines (TNF-α and IL-6). To study the possible source of
plasma mtDNA, bivariate correlation analysis was used
and demonstrated that the peak MPV/platelet count ra-
tio was positively correlated with the peak plasma
Fig. 1 Changes of perioperative platelets activation level. Platelets count decreased significantly at the end of CPB (T2) and increased from T3 to
T6 (P < 0.05). Mean platelet volume (MPV) increased at T2 and then back to normal gradually (P < 0.05). MPV/platelet count increased significantly
at T2 and decreased from T3 to T6 (P < 0.05). *P < 0.05 vs. T1. T1: before induction of anaesthesia; T2: at the end of CPB; T3: 12 h post-CPB; T4:
24 h post-CPB; T5: 48 h post-CPB; T6: 72 h post-CPB. Units of left y axis (platelet count): ×109 per litre; Units of left y axis (MPV): femtoliter (fl)
Qin et al. Journal of Cardiothoracic Surgery  (2016) 11:90 Page 4 of 9
mtDNA level. Subgroup analysis also suggested that pa-
tients with CPB with higher peak MPV/platelet count
ratio had higher post-CPB plasma mtDNA level and
higher systemic inflammatory level.
During cardiac surgery with CPB, the blood flows out
of the vessels and goes through the circuits. A large
number of studies demonstrated that exposure of blood
to the bypass circuit surface initiated systemic inflamma-
tory responses, taking responsibility for post-CPB in-
flammation and organ dysfunction [17]. It is well known
that the activation of platelets during the CPB could
cause post-CPB inflammatory responses. Additionally,
some studies revealed that activated platelets played its
role in inflammation via expression of P-selectin and
CD40 ligand [18, 19]. Recently, Procter NE, et al identi-
fied that the hyper-aggregability of platelets could cause
inflammation through MPO-related pathway in patients
with atrial fibrillation [20]. Therefore, anti-coagulation
strategy was widely used in the cardiac surgery with CPB
and heparin-coated circuits were also applied to abate
the inflammation and coagulation [21]. In our study, we
illustrated the dynamic changes of platelets activation
Fig. 2 a Variation of plasma mtDNA during the cardiac surgery with CPB and the correlation between peak activation level of platelets and peak
plasma mtDNA level. Plasma mtDNA level increased significantly and peaked at T3, which decreased slowly from T3 to T6 (P < 0.05). b Bivariate
correlation study showed a positive correlation between peak activation level of platelets and peak plasma mtDNA level (r = 0.683, P < 0.0001).
*P < 0.05 vs. T1. Units of y axis: copies per microliter (copies/μL)
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during the cardiac surgery with CPB. Unsurprisingly,
rapid activation of platelets was shown and activation
level peaked at the end of CPB. Meanwhile, post-CPB
inflammatory level was also shown in our study and
the peak level of inflammatory responses occurred at
12 h post-CPB, which is 12 h later than the peak point
of platelets activation. Given the well-known pro-
inflammatory properties of activated platelets, our data
suggested that activation of platelets might promote
post-CPB inflammatory responses.
Although many studies focused on the mechanism be-
tween activated platelets and inflammation, it was still
not fully understood. In our previous study, a tight and
strong relationship between post-CPB plasma mtDNA
level and plasma inflammatory cytokines was revealed.
Therefore, elevated plasma mtDNA was regarded as a
pro-inflammatory agent during the cardiac surgery with
CPB and promoted post-CPB inflammatory responses. A
study conducted by Luc H. Boudreau, et al suggested
that activated platelets can release mitochondria and
mtDNA. Transfused patients and in vitro platelets acti-
vation study were used to evaluate the mtDNA changes
[15]. Platelets, as small discoid anucleate cell fragment
from megakaryocytes, contained cytoplasmic organelles,
including mitochondria. After the activation of platelets,
intracellular components were released via the cyto-
plasmic granules formation and the fusion with the
plasma membrane [22]. Given that the perioperative
variation of plasma mtDNA level we studied, it is pos-
sible that most of post-CPB plasma mtDNA were from
activated platelets. In our study, we found the peak
platelets activation time is T2 and peak mtDNA level
occurred at T3, which mean that the mtDNA elevation
came after the platelets activation. Bivariate correlation
analysis was applied to study the correlation between
peak platelets activation level and peak plasma mtDNA
level. Since the time gap and positive correlation, our
results suggested that activated platelets might be the
source of plasma mtDNA during the cardiac surgery
with CPB.
Fig. 3 Merged curve of perioperative inflammatory cytokines in
the cardiac surgery with CPB. Both TNF-α and IL-6 were elevated
significantly after CPB (P < 0.05). Levels of TNF-α and IL-6 peaked at
T3 (P < 0.05). *P < 0.05 vs. respective T1. Units of y axis: picogram
per milliliter (pg/mL)
Fig. 4 Distribution of study population according to the activation level of platelets
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MtDNA has been widely studied recently, which could
cause systemic inflammation when it was released into
the circulation [23]. Plasma mtDNA was captured into
leukocytes and acts as bacteria to cause inflammatory re-
sponses [24]. Studies found that plasma mtDNA level
can represent the invasiveness and complexation of sur-
geries [25]. In vivo study revealed that injection of
mtDNA can cause severe systemic inflammatory re-
sponses and multiple organ dysfunction [23]. Consistent
with our previous study, mtDNA level after cardiac sur-
gery was correlated with inflammatory response level.
And in the present study, we concluded that activated
platelets may take responsibilities for the elevated
mtDNA level. However, many other factors are also
considered to account for elevated mtDNA. Many
studies reported the myocardial ischemia/reperfusion
injuries after cardiac surgery with CPB [26, 27]. During
the ischemia/reperfusion injury, myocardial tissue dam-
age may cause mtDNA releases. Also, the damage of
surgery itself to the heart can cause tissue damage and
mtDNA release.
In order to further study the relationship between acti-
vated platelets and plasma mtDNA, we conducted the
subgroup analysis. Four quartiles according to platelets
activation levels were set. Unsurprisingly, patients with
higher platelets activation level presented higher level of
plasma mtDNA and suffered higher level of post-CPB
inflammation. Levels of TNF-α and IL-6 represented the
severity of post-CPB inflammatory responses [28]. Post-
CPB inflammation might cause a delay of the recovery
Table 2 Subgroup analysis
MPV/platelet count
Quartile 1 Quartile 2 Quartile 3 Quartile 4
< 0.09 0.09–0.11 0.11–0.13 > 0.13
Number 14 17 22 15
Age (years) 46.5 ± 9.2 47.1 ± 6.0 47.8 ± 8.3 48.4 ± 12.5
Women 9 9 15 8
BMI 23.4 ± 3.5 24.1 ± 2.7 24.5 ± 3.1 23.7 ± 3.8
BSA (m2) 1.7 ± 0.2 1.8 ± 0.3 1.8 ± 0.2 1.8 ± 0.3
Stable angina 3 3 4 2
Unstable angina 4 5 5 4
STEMI 5 5 8 6
NSTEMI 2 4 5 3
Surgical information
Aortic cross-clamping time (min) 64.3 ± 21.7 63.1 ± 20.6 64.7 ± 22.3 66.3 ± 19.8
Total CPB time (min) 96.0 ± 26.3 96.4 ± 28.1 96.1 ± 25.9 98.3 ± 30.2
Laboratory data
serum creatinine (μmol/L) 0.6 ± 0.2 0.6 ± 0.3 0.5 ± 0.3 0.6 ± 0.2
TC (mg/dL) 203.7 ± 31.6 200.1 ± 39.3 201.4 ± 36.7 207.2 ± 45.3
HDL (mmol/L) 1.2 ± 0.4 1.2 ± 0.2 1.3 ± 0.3 1.3 ± 0.2
LDL (mmol/L) 3.1 ± 0.5 2.9 ± 0.4 3.0 ± 0.4 3.0 ± 0.4
TG (mmol/L) 1.8 ± 0.3 1.7 ± 0.4 1.7 ± 0.2 1.8 ± 0.3
Glucose (mg/dL) 132.1 ± 31.4 139 ± 30.7 121.5 ± 36.3 145.3 ± 31.1
RBC (×1012/L) 4.4 ± 0.4 4.2 ± 0.3 4.3 ± 0.3 4.1 ± 0.5
WBC (×1012/L) 5.6 ± 1.5 4.9 ± 1.7 6.4 ± 1.3 6.0 ± 1.0
Hemoglobin (g/L) 125.2 ± 11.9 123.8 ± 14.9 130.1 ± 11.3 122.5 ± 10.1
Hematocrit (%) 38.2 ± 3.7 38.1 ± 3.2 38.4 ± 5.3 37.2 ± 3.9
MPV/platelet count ratio 0.08 ± 0.009 0.10 ± 0.010 0.12 ± 0.009 0.14 ± 0.011
Plasma mtDNA (copies/μL) 798 ± 49 889 ± 65* 953 ± 87* 1021 ± 58*
TNF-α (pg/mL) 164 ± 39 204 ± 42* 294 ± 37* 337 ± 29*
IL-6 (pg/mL) 181 ± 43 223 ± 38* 298 ± 42* 328 ± 37*
Variables are presented as mean ± SD or as numbers. BMI body mass index, BSA body surface area, STEMI ST-segment myocardial infarction, NSTEMI Non-ST-
segment myocardial infarction, CPB cardiopulmonary bypass, TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, TG triglycerides, RBC
red blood cell, WBC white blood cell, MPV mean platelet volume, TNF-α tumor necrosis factor-α, IL-6 interleukin-6. *P < 0.05 vs. respective Quartile 1
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and deteriorate the hospital outcomes [29]. Above all,
our data revealed the tight association between platelets
activation and elevated plasma mtDNA level, suggesting
that activated platelets might cause post-CPB inflamma-
tion through releasing mtDNA.
Although we got some excellent results, our study still
has many limitations. Our study only enrolled sixty-
eight patients undergoing CABG with CPB. To further
study the relationships among platelets, mtDNA and in-
flammatory responses, a large-scale study is needed.
Additionally, more specific and statistical grouping and
subgrouping setting should be designed. Moreover, we
still need further experiments or clinic study to achieve
the direct evidences to prove our speculation. Finally,
our study can only provide a preliminary result about
the role of mtDNA in platelets-mediated post-CPB in-
flammatory responses, but raise a clinical foundation for
further relative studies.
Conclusion
Our study demonstrated the positive correlation be-
tween platelets activation and peak plasma mtDNA level
during the cardiac surgery with CPB, which explains the
possible source of abundant plasma mtDNA after CPB.
Therefore, in combination with our previous study, we
raised a novel potential theory that mtDNA might act as
a mediator between platelets and inflammation after car-
diac surgery with CPB and platelets might act as a valu-
able target to modify the inflammation.
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